Your browser is no longer supported. Please, upgrade your browser.
CATB Catabasis Pharmaceuticals, Inc. daily Stock Chart
Catabasis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.23 Insider Own0.57% Shs Outstand15.90M Perf Week0.33%
Market Cap108.78M Forward P/E- EPS next Y-1.55 Insider Trans0.00% Shs Float17.63M Perf Month8.82%
Income-28.20M PEG- EPS next Q-0.43 Inst Own45.00% Short Float2.11% Perf Quarter20.04%
Sales- P/S- EPS this Y54.10% Inst Trans27.13% Short Ratio2.37 Perf Half Y15.98%
Book/sh3.38 P/B1.83 EPS next Y6.60% ROA-58.40% Target Price- Perf Year-10.06%
Cash/sh3.13 P/C1.97 EPS next 5Y- ROE-66.00% 52W Range2.74 - 8.19 Perf YTD4.40%
Dividend- P/FCF- EPS past 5Y31.70% ROI- 52W High-24.66% Beta1.76
Dividend %- Quick Ratio12.40 Sales past 5Y- Gross Margin- 52W Low125.18% ATR0.36
Employees27 Current Ratio12.40 Sales Q/Q- Oper. Margin- RSI (14)61.74 Volatility5.46% 6.57%
OptionableYes Debt/Eq0.00 EPS Q/Q19.80% Profit Margin- Rel Volume0.73 Prev Close6.21
ShortableYes LT Debt/Eq0.00 EarningsMay 12 AMC Payout- Avg Volume157.01K Price6.17
Recom1.00 SMA201.96% SMA5019.37% SMA20014.00% Volume114,673 Change-0.64%
Oct-05-17Reiterated Oppenheimer Outperform $4 → $7
Feb-02-17Downgrade Citigroup Buy → Neutral
Dec-22-16Initiated H.C. Wainwright Buy $14
Jun-08-16Reiterated Wedbush Outperform $27 → $17
Jul-20-15Initiated Wedbush Outperform $27
Jul-20-15Initiated Oppenheimer Outperform $28
Jul-20-15Initiated Citigroup Buy $21
May-12-20 04:10PM  
May-07-20 09:30AM  
Apr-28-20 08:00AM  
Apr-17-20 08:00AM  
Mar-27-20 03:22AM  
Mar-25-20 08:00AM  
Mar-24-20 04:00PM  
Mar-18-20 08:00AM  
Mar-14-20 09:32AM  
Mar-10-20 08:05AM  
Feb-25-20 08:00AM  
Feb-21-20 08:00AM  
Feb-03-20 04:05PM  
Jan-30-20 09:00AM  
Jan-29-20 04:01PM  
Jan-09-20 04:09PM  
Jan-08-20 08:00AM  
Dec-24-19 06:15AM  
Dec-23-19 02:15PM  
Dec-16-19 08:00AM  
Nov-25-19 06:45PM  
Nov-18-19 06:53AM  
Nov-07-19 08:05AM  
Oct-24-19 08:00AM  
Oct-19-19 09:26AM  
Oct-18-19 08:00AM  
Oct-05-19 08:00AM  
Sep-30-19 04:05PM  
Sep-27-19 08:00AM  
Sep-26-19 08:00AM  
Sep-25-19 08:00AM  
Sep-19-19 10:13AM  
Aug-20-19 10:58AM  
Aug-09-19 05:04PM  
Aug-08-19 08:05AM  
Aug-07-19 08:00AM  
Aug-06-19 08:00AM  
Jul-25-19 08:30AM  
Jul-15-19 03:08PM  
Jun-27-19 08:00AM  
Jun-21-19 09:45AM  
Jun-18-19 08:00AM  
Jun-07-19 09:24AM  
May-15-19 06:33PM  
May-14-19 08:05AM  
May-02-19 08:00AM  
Apr-30-19 08:00AM  
Apr-26-19 03:26PM  
Apr-12-19 11:34AM  
Apr-01-19 08:00AM  
Mar-26-19 12:11PM  
Mar-19-19 12:26PM  
Mar-18-19 09:02AM  
Mar-14-19 06:09PM  
Mar-13-19 08:00AM  
Mar-08-19 09:54AM  
Mar-07-19 08:57AM  
Mar-06-19 01:56PM  
Feb-28-19 08:00AM  
Feb-19-19 08:00AM  
Feb-14-19 08:00AM  
Feb-06-19 09:00AM  
Feb-05-19 04:01PM  
Jan-29-19 07:55AM  
Jan-15-19 11:10AM  
Jan-14-19 01:42AM  
Jan-11-19 09:30AM  
Jan-08-19 08:38AM  
Jan-04-19 08:00AM  
Jan-03-19 08:08AM  
Dec-31-18 04:31PM  
Dec-24-18 08:00AM  
Dec-18-18 08:12AM  
Dec-12-18 02:22AM  
Nov-28-18 08:55AM  
Nov-27-18 08:00AM  
Nov-16-18 05:48PM  
Nov-15-18 09:26AM  
Nov-13-18 08:15AM  
Nov-02-18 08:00AM  
Oct-30-18 08:00AM  
Oct-18-18 08:25AM  
Oct-17-18 02:20PM  
Oct-04-18 09:20AM  
Oct-03-18 08:00AM  
Sep-25-18 08:00AM  
Sep-19-18 08:00AM  
Sep-13-18 09:13AM  
Aug-27-18 07:45AM  
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activate B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). It is also involved in developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD; and collaboration with the University of Texas Southwestern to study the potential benefits of edasalonexent treatment. The company also has a preclinical research collaboration with the Jain Foundation to study edasalonexent (CAT-1004) in Dysferlinopathy. The company was founded in 2008 and is based in Cambridge, Massachusetts.